Previsioni

Acquista	0
Mantieni	1
Vendi	0

Notizie Vai al feed delle notizie

Northwest Biotherapeutics secures $4.9m convertible note with Yorkville

Northwest Biotherapeutics has closed a $4.9 million convertible note with YA II PN, Ltd. (managed by Yorkville Advisors) to bridge acute liquidity shortfalls. The unsecured, non‑interest‑bearing note runs for 12 months, is issued with a 5% original issue discount and can be converted by the holder prior to maturity into shares at a small discount. In addition, there is a voluntary standby equity purchase agreement of up to $50 million within 24 months and a warrant of up to $2 million at $0.205 per share. The proceeds are for general corporate purposes and to support the lead product; however, the company has a very weak balance sheet (current ratio 0.07; levered FCF -$49.4 million) and the stock fell nearly 40% over six months. » Altro su de.investing.com
Northwest Biotherapeutics: CTO presents DCVax-L study results at neuro-oncology congress

CTO Dr. Marnix Bosch of Northwest Biotherapeutics will present analyses of survival extension from DCVax-L using propensity score matching at the 2026 annual meeting of the British Neuro-Oncology Society. The presentation, titled “DCVax-L Associated Survival Extension Assessed Through Propensity Score Matching Analyses,” will take place on Friday at 10:00 GMT; the slides will be published afterward on the company website. Northwest is a clinical-stage biotech with a completed phase III trial (331 patients) of DCVax-L and an ongoing regulatory review in the United Kingdom. The stock trades near its 52-week low at $0.18; data show high cash outflows and continued lack of profitability. » Altro su de.investing.com
Northwest Biotherapeutics completes acquisition of Advent BioServices

Northwest Biotherapeutics has completed the acquisition of Advent BioServices; the transaction closed on October 24, 2025. The purchase price is about $1.9 million, payable in installments over two years with 7.5% interest on the unpaid balance, and Northwest assumes roughly $8.3 million of net liabilities for services previously provided. The deal is classified as a related-party transaction because CEO Linda Powers is the controlling member of the seller; the SEC granted an exemption under Rule 3-13. The company also settled a Delaware lawsuit, with insurers paying $2.25 million and 17% of the disputed 2020 option grants being cancelled. » Altro su de.investing.com

Dati finanziari dell'azienda

Nell'ultimo trimestre, Northwest Biotherapeutics ha registrato ricavi pari a 707.10k€ e un utile netto di −8.08m€

(EUR)	giu 2026	YoY
Ricavi	+707.10k	536,21%
Utile lordo	−39.43k	135,48%
Utile netto	−8.08m	38,07%
EBITDA	−9.42m	14,80%

Dati fondamentali

Metrica	Valore
Capitalizzazione di mercato	+245.31m€
Numero di azioni	1.64b
Massimo/minimo a 52 settimane	+0,32€ - +0,12€
Dividendi	No
Beta	-0,62
Rapporto P/E	−7,01
Rapporto PEG	−0,07
Rapporto P/B	−8,21
Rapporto P/S	+131,51

Profilo aziendale

Northwest Biotherapeutics, Inc. ist ein Biotechnologieunternehmen, das in den Vereinigten Staaten und international personalisierte Immuntherapien gegen Krebs entwickelt. Das Unternehmen entwickelt seine Produkte auf der Grundlage von DCVax, einer Plattformtechnologie, die aktivierte dendritische Zellen einsetzt, um das eigene Immunsystem des Patienten zur Bekämpfung von Krebs zu mobilisieren. Sein führendes Produkt, DCVax-L, hat die klinischen Studien der Phase III zur Behandlung von Glioblastoma multiforme-Hirnkrebs abgeschlossen. Das Unternehmen entwickelt auch DCVax-Direct, das sich in klinischen Studien der Phase I/II zur Behandlung inoperabler solider Tumore befindet. Das Unternehmen wurde 1996 gegründet und hat seinen Hauptsitz in Bethesda, Maryland.

Nome	Northwest Biotherapeutics
CEO	Linda F. Powers
Sede centrale	Bethesda, md Stati Uniti
Sito web	nwbio.com
Settore	Materiali
Industria	Prodotti chimici
Quotazione in borsa	14/12/2001
Dipendenti	105